Arcus Biosciences opened lower at $18.34, compared with its previous close of $18.80. In the last trading session, the stock traded between $17.77 and $18.65. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Arcus Biosciences is now worth
$ 47.48
Resulting in a loss of
$ 52.52 (52.52%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 12 Analysts
Buy
83.33%
Hold
16.67%
Sell
0%
Markets Today
Today's Change
$-1.03 (-5.45%)
Day High
$18.65
Day Low
$17.77
Day Open
$18.34
Prev Close
$18.80
Volume
7,52,839
1W Return
-8.18%
1M Return
-26.98%
3M Return
-38.18%
6M Return
-28.50%
1Y Return
-12.40%
Fundamentals
Market Cap ($ Mn)
2,559
PE Ratio
-
PB Ratio
7.99
PEG Ratio
-
ROE
-67.06%
ROCE
-43.86%
EPS (TTM)
$-1.00
Investment Returns
1 Week
-8.18%
1 Month
-26.98%
3 Months
-38.18%
6 Months
-28.50%
9 Months
-16.78%
Financials
Quarterly
All values in $ Mn
28.0
Mar 25
160.0
Jun 25
26.0
Sep 25
33.0
Dec 25
41.0
Jun 26
9.0
Sep 26
Updates
6Nov
Leerink Partners maintains Outperform on Arcus Biosciences, raises PT to $49
Leerink Partners maintains Outperform rating on Arcus Biosciences. Price target raised from $46 to $49 per share. Analyst Daina Graybosch issued the rating update.
7 days ago
5Nov
Truist Securities maintains Buy on Arcus Biosciences, trims PT to $40
Truist Securities maintains a Buy rating on Arcus Biosciences. Price target lowered from $41 to $40 by analyst Supawat Thongthip. Rating status remains unchanged despite the reduced valuation.
7 days ago
22Oct
Arcus Biosciences commences underwritten public offering of common stock
Arcus Biosciences has commenced an underwritten public offering of its common stock. Underwriters have a 30-day option to purchase up to an additional 15% of shares. Jefferies, Leerink Partners, and TD Cowen serve as joint book-running managers. Shelf registration statement was filed with the SEC on February 25, 2026.
22 days ago
22Oct
Citigroup raises Arcus Biosciences price target to $50, maintains Buy
Citigroup maintains Buy rating on Arcus Biosciences. Price target raised from $45 to $50. Analyst Yigal Nochomovitz issued the update.
22 days ago
16Oct
William Blair initiates coverage on Arcus Biosciences with Outperform rating
William Blair initiated coverage on Arcus Biosciences. Analyst Alethia Young assigned an Outperform rating. The rating suggests a positive outlook for the stock.
27 days ago
10Oct
Arcus Biosciences grants equity awards to two new employees
Granted options for 9,150 shares at $23.83 exercise price. Issued RSUs for 4,600 shares to two new employees. Awards made under 2020 Inducement Plan via NYSE Rule 303A.08. Exercise price reflects closing stock price on October 8, 2026.
